[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Rheumatoid Arthritis Drugs/Therapeutics Market Size study, by Molecule Type (Biopharmaceuticals, Pharmaceuticals), by Sales Channel (Prescription, Over the Counter (OTC)) and Regional Forecasts 2019-2026

June 2019 | 200 pages | ID: G0D92CA2B5DEN
Bizwit Research & Consulting LLP

US$ 3,160.00 US$ 3,950.00 -20 %
Offer valid until January 20, 2020!

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Rheumatoid Arthritis Drugs/Therapeutics Market valued approximately USD 22.14 billion in 2018 is anticipated to grow with a healthy growth rate of more than 4.50% over the forecast period 2019-2026. The Rheumatoid Arthritis Drugs/Therapeutics Market is continuously growing in the global scenario at significant pace. Rheumatoid arthritis (RA) is the most common type of autoimmune chronic disease that causes joint pain, swelling and stiffness in joint and even loss of joint function. To overcome this diseases various medications are introduced such as disease-modifying anti-rheumatic drugs (DMARDs), biological response modifiers (a type of DMARD), glucocorticoids, analgesics (painkillers) and nonsteroidal anti-inflammatory medications (NSAIDs). DMARDs have significantly enhanced the quality of life for numerous people suffering from rheumatoid arthritis. Rising geriatric population worldwide, increasing prevalence of rheumatoid and structured reimbursement & regulatory framework are the substantial driving factors of the market during the forecast period. Additionally, increasing awareness regarding diseases remittances therapies and growing healthcare expenditure are another factor that impelling the demand of rheumatoid arthritis drugs across the globe. Moreover, rise in need of Rheumatoid Arthritis Drugs/Therapeutics due to increasing prevalence of disease is the factors that likely to create numerous opportunity in the near future. However, patient expiration of many leading drugs is one of the major factors that limiting the growth of the market during the forecast period.

The regional analysis of Global Rheumatoid Arthritis Drugs/Therapeutics Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share due to rising awareness associated with the disease, growing healthcare expenditure and high adoption of biopharmaceuticals for the treatment in the region. Europe is estimated to grow at stable growth rate in the global Rheumatoid Arthritis Drugs/Therapeutics market over the upcoming years. Further, Asia-Pacific is anticipated to exhibit higher growth rate / CAGR over the forecast period 2019-2026 due to increasing adoption of rheumatoid arthritis drugs in the region.

The major market player included in this report are:
Abb Vie
Amgen Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb
F. Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
UCB S.A.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Molecule Type:

Biopharmaceuticals
Pharmaceuticals

By Sales Channel:

Prescription
Over the Counter (OTC)

By Regions:

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026

Target Audience of the Global Rheumatoid Arthritis Drugs/Therapeutics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
CHAPTER 1. EXECUTIVE SUMMARY

1.1. Market Snapshot
1.2. Key Trends
1.3. Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
  1.3.1. Rheumatoid Arthritis Drugs/Therapeutics Market, by Molecule Type, 2016-2026 (USD Billion)
  1.3.2. Rheumatoid Arthritis Drugs/Therapeutics Market, by Sales Channel, 2016-2026 (USD Billion)
  1.3.3. Rheumatoid Arthritis Drugs/Therapeutics Market, by Region, 2016-2026 (USD Billion)
1.4. Estimation Methodology
1.5. Research Assumption

CHAPTER 2. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET DEFINITION AND SCOPE

2.1. Objective of the Study
2.2. Market Definition & Scope
  2.2.1. Industry Evolution
  2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates

CHAPTER 3. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET DYNAMICS

3.1. See Saw Analysis
  3.1.1. Market Drivers
  3.1.2. Market Challenges
  3.1.3. Market Opportunities

CHAPTER 4. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET INDUSTRY ANALYSIS

4.1. Porter’s 5 Force Model
  4.1.1. Bargaining Power of Buyers
  4.1.2. Bargaining Power of Suppliers
  4.1.3. Threat of New Entrants
  4.1.4. Threat of Substitutes
  4.1.5. Competitive Rivalry
  4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.2. PEST Analysis
  4.2.1. Political Scenario
  4.2.2. Economic Scenario
  4.2.3. Social Scenario
  4.2.4. Technological Scenario
4.3. Key Buying Criteria (On Demand)
4.4. Regulatory Framework (On Demand)
4.5. Investment Vs Adoption Scenario (On Demand)
4.6. Analyst Recommendation & Conclusion

CHAPTER 5. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, BY MOLECULE TYPE

5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Key Market Players
5.4. Rheumatoid Arthritis Drugs/Therapeutics Market, Sub Segment Analysis
  5.4.1. Biopharmaceuticals
    5.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    5.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  5.4.2. Pharmaceuticals
    5.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    5.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

CHAPTER 6. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, BY SALES CHANNEL

6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Key Market Players
6.4. Rheumatoid Arthritis Drugs/Therapeutics Market, Sub Segment Analysis
  6.4.1. Prescription
    6.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    6.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  6.4.2. Over the Counter (OTC)
    6.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    6.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

CHAPTER 7. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, BY REGIONAL ANALYSIS

7.1. Rheumatoid Arthritis Drugs/Therapeutics Market, Regional Market Snapshot (2016-2026)
7.2. North America Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
  7.2.1. U.S.
    7.2.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.2.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.2.1.3. Sales Channels breakdown estimates & forecasts, 2016-2026 (USD Billion)
  7.2.2. Canada
    7.2.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.2.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.2.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.3. Europe Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
  7.3.1. U.K.
    7.3.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.3.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.3.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  7.3.2. Germany
    7.3.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.3.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.3.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  7.3.3. Rest of Europe
    7.3.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.3.3.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.3.3.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4. Asia Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
  7.4.1. China
    7.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.4.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.4.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  7.4.2. India
    7.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.4.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.4.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  7.4.3. Japan
    7.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.4.3.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.4.3.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  7.4.4. Rest of Asia Pacific
    7.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.4.4.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.4.4.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.5. Latin America Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
  7.5.1. Brazil
    7.5.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.5.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.5.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  7.5.2. Mexico
    7.5.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.5.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.5.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.6. Rest of The World
  7.6.1. South America
    7.6.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.6.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.6.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  7.6.2. Middle East and Africa
    7.6.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    7.6.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    7.6.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

CHAPTER 8. COMPETITIVE INTELLIGENCE

8.1. Company Market Share (Subject to Data Availability)
8.2. Top Market Strategies
8.3. Company Profiles
  8.3.1. Abb Vie
    8.3.1.1. Overview
    8.3.1.2. Financial (Subject to Data Availability)
    8.3.1.3. Summary
    8.3.1.4. Recent Developments
  8.3.2. Amgen Inc.
  8.3.3. Boehringer Ingelheim GmbH
  8.3.4. Bristol-Myers Squibb
  8.3.5. F. Hoffmann-La Roche AG
  8.3.6. Johnson & Johnson
  8.3.7. Novartis International AG
  8.3.8. Pfizer Inc.
  8.3.9. Regeneron Pharmaceuticals Inc.
  8.3.10. UCB S.A.

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process
  9.1.1. Data Mining
  9.1.2. Analysis
  9.1.3. Market Estimation
  9.1.4. Validation
  9.1.5. Publishing
  9.1.6. Research Assumption


More Publications